Skip to search formSkip to main contentSkip to account menu

ACT-078573

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
To examine the role of orexin-1 and orexin-2 receptor activity on ethanol self-administration, compounds that differentially… 
2014
2014
Cannabinoid CB1 and orexin OX1 receptors have been suggested to form heterodimers and oligomers. Aimed at studying these… 
Review
2010
Review
2010
  • D. Neubauer
  • Current opinion in investigational drugs
  • 2010
  • Corpus ID: 2344908
Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in… 
2007
2007
Brisbare-Roch et al. reply: We agree with Tafti that animal and human orexin deficiency syndromes suggest a theoretical risk of… 
Review
2007
Review
2007
  • C. Wiedemann
  • Nature Reviews Drug Discovery
  • 2007
  • Corpus ID: 24218480
10.1038/nrd2277 The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic… 
2007
2007
  • O. Young
  • Lab Animal
  • 2007
  • Corpus ID: 77606315
A newly identified compound selectively blocks receptors for the protein that narcoleptics lack. The drug has the apparent… 
2007
2007
  • C. Wiedemann
  • Nature Reviews Neuroscience
  • 2007
  • Corpus ID: 35837576
The sleep–wake cycle in mammals is tightly regulated by the levels of orexins, a family of two hypothalamic peptides. During…